CASTLE BIOSCIENCES INCCSTLEarnings & Financial Report
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
CSTL Q1 FY2026 Key Financial Metrics
Revenue
$83.7M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-14.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-17.4%
YoY Growth
-4.9%
EPS
$-0.49
CASTLE BIOSCIENCES INC Q1 FY2026 Financial Summary
CASTLE BIOSCIENCES INC reported revenue of $83.7M (down 4.9% YoY) for Q1 FY2026, with a net profit of $-14.5M (up 43.8% YoY) (-17.4% margin).
Key Financial Metrics
| Total Revenue | $83.7M |
|---|---|
| Net Profit | $-14.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
CASTLE BIOSCIENCES INC Annual Revenue by Year
CASTLE BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $344.2M).
CASTLE BIOSCIENCES INC Quarterly Revenue & Net Profit History
CASTLE BIOSCIENCES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $83.7M | -4.9% | $-14.5M | -17.4% |
| Q4 FY2025 | $87.0M | +0.8% | N/A | N/A |
| Q3 FY2025 | $83.0M | -3.2% | $-501.0K | -0.6% |
| Q2 FY2025 | $86.2M | -0.9% | $4.5M | 5.2% |
| Q1 FY2025 | $88.0M | +20.6% | $-25.8M | -29.4% |
| Q4 FY2024 | $86.3M | +30.5% | N/A | N/A |
| Q3 FY2024 | $85.8M | +39.5% | $2.3M | 2.6% |
| Q2 FY2024 | $87.0M | +73.5% | $8.9M | 10.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.0M | $85.8M | $86.3M | $88.0M | $86.2M | $83.0M | $87.0M | $83.7M |
| YoY Growth | 73.5% | 39.5% | 30.5% | 20.6% | -0.9% | -3.2% | 0.8% | -4.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $487.3M | $514.6M | $531.2M | $501.7M | $544.7M | $562.8M | $578.6M | $547.8M |
| Liabilities | $63.4M | $73.5M | $75.4M | $61.4M | $89.4M | $95.7M | $107.7M | $86.4M |
| Equity | $423.9M | $441.1M | $455.8M | $440.3M | $455.4M | $467.0M | $470.9M | $461.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $24.0M | $23.3M | $24.4M | $-6.0M | $20.8M | $22.6M | $26.9M | $-22.1M |